# Aisimai

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aisimai

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Website: www.excelmab.com
- Total disclosed funding: $0.7M
- Latest round: Series A (Mar 11, 2020)
- Investors on record: 6

## About

Established in 2016 and based in Guangzhou, China, Aisimai is a biomedical developer that focuses on bispecific antibody drugs. Dr. Wenjun Zhang, the CEO of the company, once served as the R&D staff of Novartis and MacroGenics. More than 20% of the core research team has master's degree. The company cooperates with Zhenge Biotech, OPM and Joinn.

The company provides dual-targeted antibody drugs for tumor treatment field, such as gastric cancer, breast cancer and rheumatoid arthritis. The product of the company includes EX103 and EX101. The company adopts antibody discovery and verification platform and bispecific antibody platform ExMab®, including antibody engineering construction and screening and clinical medication.

The company will increase the investment of developing new products and declare investigational new drug(IND).

## Funding rounds

- Series A, Mar 11, 2020 — CAS Investment Management, Korea Investment Partners, MED-FINE Capital, Elite Capital
- Angel, Feb 28, 2017, $0.7M — Oriza Holdings, YuanBio Venture

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Angel
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Angel
- CAS Investment Management (https://capitalatlas.ai/funds/cas-investment-management) — Series A
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series A
- Elite Capital (https://capitalatlas.ai/funds/elite-capital) — Series A